Benefits
Age-Related Macular Degeneration (AMD) — Early Stage
Multiple RCTs of saffron 20-30 mg/day showed improved retinal flicker sensitivity in early-stage AMD patients. Falsini 2010 and subsequent studies established saffron-specific AMD evidence base. AffronEYE delivers standardized crocins.
Long-Term Open-Label AMD Extension
Recent open-label extension trial of 93 adults >50 with mild/moderate AMD showed long-term saffron treatment was safe and beneficial for ongoing AMD management. Clinical relevance for chronic AMD support.
Macular Pigment / Retinal Antioxidant Protection
Crocins protect photoreceptor cells from oxidative stress; cross blood-retina barrier; act as macular antioxidants protecting against blue light damage and AMD progression.
Fast Absorption (1.5 Hours)
Distinguishes from lutein/zeaxanthin which require longer for tissue saturation. Crocin maximum blood concentration reached in 1.5 hours after AffronEYE consumption.
Glaucoma Prevention (Animal Evidence)
Animal study suggests AffronEYE saffron may help prevent glaucoma onset. Early-stage evidence; clinical translation pending.
AREDS2 Adjunct / Alternative
AREDS2 supplements (lutein + zeaxanthin + zinc + antioxidant vitamins) are foundational for AMD; saffron provides complementary mechanism. AffronEYE combinable with AREDS2 protocol or used standalone.
Mechanism of action
Crocin Macular Antioxidant Activity
Crocins are water-soluble carotenoid glycosides — unique among carotenoids for water solubility (lutein/zeaxanthin are lipid-soluble). Cross blood-retina barrier; accumulate in retinal tissue; protect photoreceptor cells from oxidative stress.
Blood Flow / Microcirculation Enhancement
Crocins improve retinal microcirculation — relevant to AMD progression where retinal hypoperfusion contributes to pathology.
Photoreceptor Protection
Direct protection of photoreceptor cells (rods and cones) from oxidative damage and apoptosis. Mechanism for retinal flicker sensitivity improvements in AMD trials.
Anti-Inflammatory / Neuroprotective
Saffron compounds reduce retinal inflammation and provide neuroprotective effects relevant to AMD pathology.
Faster Bioavailability vs Other Carotenoids
Water solubility enables faster absorption than lipid-soluble carotenoids; rapid systemic delivery to retinal tissue.
Clinical trials
Pioneering RCT of saffron supplementation on retinal flicker sensitivity in early AMD patients.
Early-stage AMD patients.
Significant improvement in retinal flicker sensitivity vs placebo. Established saffron's specific eye health applications. Foundation for AffronEYE positioning.
Open-label extension trial of saffron in 93 adults >50 with mild/moderate AMD for long-term safety and efficacy.
93 adults >50 with mild/moderate AMD.
Long-term saffron treatment safe and beneficial for ongoing AMD management. Established chronic-use evidence.
About this ingredient
AFFRONEYE® is a STANDARDIZED SAFFRON EXTRACT FOR EYE HEALTH developed by PHARMACTIVE BIOTECH PRODUCTS (Spain). Sourced from high-quality SPANISH SAFFRON (Crocus sativus L.).
KEY ACTIVE: CROCINS — carotenoid glycosides; major water-soluble pigments giving saffron its golden-yellow color; standardized to 3% by HPLC. RELATIONSHIP TO AFFRON® (mood positioning): both are Pharmactive saffron extracts; AffronEYE is positioned for eye health applications with specific 3% crocin standardization for ocular tissue effects.
KEY DISTINCTIONS: (1) FAST ABSORPTION — maximum blood crocin concentration in 1.5 hours (faster than lutein/zeaxanthin); (2) WATER-SOLUBLE — unique among major eye carotenoids; (3) STANDARDIZED 3% CROCINS by HPLC; (4) ORGANIC GRADE AVAILABLE; (5) NON-GMO; (6) Specific clinical evidence for AMD applications.
EVIDENCE-BASED USES: (1) AGE-RELATED MACULAR DEGENERATION (AMD) — early/intermediate stages; (2) Retinal flicker sensitivity improvement; (3) Macular antioxidant protection; (4) Photoreceptor protection from oxidative stress; (5) Glaucoma prevention (animal evidence); (6) AREDS2 adjunct / alternative; (7) Long-term AMD ongoing treatment.
CRITICAL CAUTIONS: (1) AMD MEDICAL MANAGEMENT — AMD requires ophthalmologist evaluation; AREDS2 supplements are evidence-based foundation; AffronEYE complementary; (2) PREGNANCY — saffron generally cautioned at supplemental doses; AVOID; (3) ANTIDEPRESSANT INTERACTION — saffron has serotonergic activity; theoretical additive effects; modest concern; (4) DOSE — 20-30 mg/day saffron equivalent in trials; AffronEYE provides higher crocin content per gram allowing flexible dosing; product specifies recommended amount; (5) DURATION — eye effects build over 3-6 months; not immediate; ongoing use needed; (6) AMD STAGE — strongest evidence in EARLY/INTERMEDIATE AMD; advanced AMD requires ophthalmological treatment (anti-VEGF injections); supplements adjunct; (7) ASTERACEAE FAMILY ALLERGY — possible cross-reactivity with ragweed, daisy family; (8) SAFFRON ADULTERATION — saffron is heavily adulterated due to high price; reputable suppliers (like Pharmactive) test for authenticity; (9) AFFRONEYE vs AFFRON — same source plant, different positioning; both Pharmactive products; AffronEYE specifically validated for eye applications; (10) AFFRONEYE vs LUTEIN/ZEAXANTHIN — different mechanisms; lutein/zeaxanthin are foundational AMD nutrients; saffron complementary; combination reasonable; (11) AFFRONEYE vs ASTAXANTHIN — both can support eye health via different mechanisms; complementary; (12) For COMPREHENSIVE EYE HEALTH — UV protection, AREDS2 (high-risk), lutein/zeaxanthin, saffron (AffronEYE), astaxanthin (VeriSperse), omega-3s, regular ophthalmologist exams; (13) BLUE LIGHT PROTECTION — crocins protect against blue light damage to photoreceptors; relevant for digital device users; (14) BRAND VERIFICATION — AffronEYE® is Pharmactive trademark; clinical evidence specific to standardized 3% crocins form; generic saffron products may vary; (15) Among the most evidence-based saffron eye health products.